MASLD and MASH: Early Identification to Decrease Associated Complications-MASLD and MASHMASLD and MASH: Early Identification to Decrease Associated Complications

MASLD and MASHMASLD and MASH: Early Identification to Decrease Associated Complications

Video Transcription

Video Summary

Dr. Cecilia Lo Wong, a professor of medicine at the University of Colorado, discussed metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. MASLD, formerly known as non-alcoholic fatty liver disease (NAFLD), involves excess liver fat with certain risk factors. MASLD can also combine with alcoholic liver disease (ALD) or other causes like celiac disease or hepatitis C. MASH, a more severe form of MASLD, leads to liver fibrosis and cirrhosis. Screening for MASLD includes assessing cardiometabolic risk factors and using tests like FIB-4 to identify high-risk individuals. Lifestyle modifications are key to managing MASLD at all stages, including weight loss, reduced alcohol consumption, and increased physical activity. Pharmacological interventions and bariatric procedures may be considered for more advanced cases. Monitoring response to therapies involves non-invasive tests like FibroScan, MRI elastography, and liver multi-scan, along with evaluating biochemical markers like ALT and AST levels. Treatments like Resmituron, GLP-1 receptor agonists, and thiazolidinediones have shown promise in improving MASLD outcomes. Ongoing clinical trials aim to further enhance treatment options for MASLD and its complications.

Keywords

metabolic dysfunction-associated steatotic liver disease

MASLD

non-alcoholic fatty liver disease

NAFLD

liver fibrosis

cirrhosis